Diamyd Medical Company
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.
Industry:
Geroscience
Headquarters:
Stockholm, Stockholms Lan, Sweden
Zip:
1-10
Founded Date:
1994-01-01
Employees Number:
1-10
Acquisitions Number:
1
Investors Number:
100000
Total Funding:
Less than $1M
Estimated Revenue:
Less than $1M
Last Funding Date:
Pre-Seed
Last Funding Type:
info@diamyd.com
Register and Claim Ownership